Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 410

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 410
---
 30, 2024, and as of and for the six -month period ended December 31, 2024 in the section of this proxy statement / prospectus entitled “Unaudited Pro Forma Combined Financial Information.” In addition to historical financial information, this discussion and analysis contains forward -looking statements based upon current expectations that involve risks, uncertainties and assumptions. See the section entitled “Cautionary Note Regarding Forward -Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward -looking statements as a result of various factors, including those set forth under “Risk Factors” or elsewhere in this proxy statement / prospectus. Overview Prior to the Heritas Contribution (as defined below), we have substantially conducted our business operations through Heritas Argentina. Heritas Argentina was incorporated on July 10, 2015 and is registered with the public registry of Rosario, circunscripciónN°1, Santa Fe, Argentina, under the number T98 F252 N12. It initially focused on developing proprietary clinical tests in genomics and reproductive health. Leveraging Bioceres’ scientific team and CIBIC’s extensive experience in clinical diagnostics, Heritas Argentina successfully launched precision medicine products and services, and it specializes in clinical genetic services, offering tests that cater to diverse medical fields such as oncology, prenatal care, and rare diseases. In response to changing consumer habits which resulted from the COVID -19pandemic, Heritas Argentina expanded its offerings by launching Rewell, a direct -to -consumerbrand focused on at -homeDNA and microbiome testing. Rewell aims to empower consumers through personalized health data to enhance their long -termwell -beingthrough optimal lifestyle choices. In addition, Rewell’s services include a secure digital platform for accessing test results and scheduling, in certain circumstances, consultations, complemented by tailored health plans aimed at prevention and wellness. In early 2025, Rewell transitioned from a direct -to-consumermodel to a business -to-business-to-consumerstrategy, leveraging partnerships with diagnostic laboratories and wellness professionals to improve scalability and economic sustainability across Latin America. This shift is aligned with OmnigenicsAI’s broader strategy to scale through a consortium -basedmodel involving local laboratory partners. Pursuant to a contribution agreement between the Parent and us, on February 26, 2024, all of the issued and outstanding shares of Heritas Argentina were contributed to us, resulting in Heritas Argentina becoming our wholly owned subsidiary (the “Heritas Contribution”).